Rockefeller Capital Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$57K Sell
521
-363
-41% -$40.5K ﹤0.01% 3380
2026
Q2
$96.7K Buy
884
+257
+41% +$26.6K ﹤0.01% 3006
2026
Q1
$65.1K Buy
627
+352
+128% +$37.5K ﹤0.01% 3128
2025
Q4
$28.4K Sell
275
-4,630
-94% -$450K ﹤0.01% 3350
2025
Q3
$443K Buy
+4,905
New +$430K ﹤0.01% 1829
2023
Q1
– Sell
-1,300
Closed -$101K – 3398
2022
Q4
$101K Hold
1,300
– – ﹤0.01% 2020
2022
Q3
$87K Hold
1,300
– – ﹤0.01% 2065
2022
Q2
$99K Buy
+1,300
New +$101K ﹤0.01% 1954

Other funds holding PPH

Rockefeller Capital Management's PPH Position: Q3 2026 in Review

Rockefeller Capital Management reduced its VanEck Pharmaceutical ETF (PPH) stake by 41% in Q3 2026, selling an estimated $40.5K and leaving 521 shares worth $57K. The position accounts for ﹤0.01% of the portfolio, ranked #3380.

Rockefeller Capital Management first reported a position in PPH in Q2 2022 and has held it in 8 quarters since. The position peaked at $443K in Q3 2025. 154 funds tracked by Wall St. Rank hold PPH as of Q3 2026.

  • Rockefeller Capital Management held 521 shares of VanEck Pharmaceutical ETF worth $57K as of Q3 2026.
  • Rockefeller Capital Management sold 363 VanEck Pharmaceutical ETF shares in Q3 2026, an estimated $40.5K.
  • VanEck Pharmaceutical ETF made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3380 holding.
  • Rockefeller Capital Management first reported a position in VanEck Pharmaceutical ETF in Q2 2022 and has held it in 8 quarters since.
  • Rockefeller Capital Management's VanEck Pharmaceutical ETF position peaked at $443K in Q3 2025.
  • 154 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.